Cargando…

Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature

Ustekinumab, a monoclonal antibody against interleukin (IL)-12 and IL-23 approved for the treatment of Crohn’s disease, has shown to be an effective therapy with a favourable safety profile. Clinical trials and real-world studies have reported very few neurological adverse events, including posterio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarto, Jordi, Caballol, Berta, Berenguer, Joan, Aldecoa, Iban, Carbayo, Álvaro, Santana, Daniel, Archilla, Ivan, Gaig, Carles, Graus, Francesc, Panés, Julián, Saiz, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883387/ https://www.ncbi.nlm.nih.gov/pubmed/35237349 http://dx.doi.org/10.1177/17562864221079682

Ejemplares similares

Image of the month: Measles inclusion body encephalitis
por: Aldecoa, Iban, et al.
Publicado: (2020)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease
por: Mishra, Avantika, et al.
Publicado: (2018)

Patients’ IgLON5 autoantibodies interfere with IgLON5-protein interactions
por: Landa, Jon, et al.
Publicado: (2023)

Corrigendum: Patients’ IgLON5 autoantibodies interfere with IgLON5–protein interactions
por: Landa, Jon, et al.
Publicado: (2023)

Ustekinumab-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn's Disease
por: Jordan, Ariel, et al.
Publicado: (2022)

Hemichorea as Presentation of Acute Cortical Ischemic Stroke. Case Series and Review of the Literature
por: Carbayo, Álvaro, et al.
Publicado: (2020)

Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study
por: Llufriu, Sara, et al.
Publicado: (2012)

CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome
por: Guasp, Mar, et al.
Publicado: (2022)

Vanishing spinal cord after varicella-zoster virus myelitis
por: Sepúlveda, María, et al.
Publicado: (2017)

Predictors of bowel damage in the long-term progression of Crohn’s disease
por: Fernández-Clotet, Agnes, et al.
Publicado: (2022)

HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease
por: Gaig, Carles, et al.
Publicado: (2019)

Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma
por: Diaz-Mercedes, Sherley, et al.
Publicado: (2019)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

Intra-Axial Frontal Cyst with Ependymoma-Like Proliferation: Neuroectodermal or Neurenteric?
por: Archilla, Ivan, et al.
Publicado: (2020)

Understanding anti-IgLON5 disease
por: Graus, Francesc, et al.
Publicado: (2017)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
por: Agusti-Mejias, Anna, et al.
Publicado: (2013)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Efficacy and safety of ustekinumab in adolescents
por: Kellen, Roselyn, et al.
Publicado: (2016)

Ustekinumab-associated disseminated verrucae
por: Anderson, Mary E., et al.
Publicado: (2018)

Sleep disorder, chorea, and dementia associated with IgLON5 antibodies
por: Simabukuro, Mateus M., et al.
Publicado: (2015)

Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease
por: Fernández-Espejo, Emilio, et al.
Publicado: (2021)

Posterior reversible encephalopathy syndrome
por: Fischer, Marlene, et al.
Publicado: (2017)

Posterior Reversible Encephalopathy Syndrome
por: Gewirtz, Alexandra N., et al.
Publicado: (2021)

Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer
por: Sabater, Lidia, et al.
Publicado: (2013)

Passive Experimental Autoimmune Encephalomyelitis in C57BL/6 with MOG: Evidence of Involvement of B Cells
por: Mannara, Francesco, et al.
Publicado: (2012)

The Diagnostic Value of Onconeural Antibodies Depends on How They Are Tested
por: Ruiz-García, Raquel, et al.
Publicado: (2020)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Bullous pemphigoid during ustekinumab therapy
por: Le Guern, Aurore, et al.
Publicado: (2015)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Ustekinumab-induced subacute cutaneous lupus
por: Tierney, Emma, et al.
Publicado: (2019)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Ustekinumab-induced fixed drug eruption
por: Hafez, Dhafer M., et al.
Publicado: (2020)

A case of ustekinumab-induced sclerouveitis
por: Godwin, Kristen S., et al.
Publicado: (2022)

Interstitial Granulomatous Drug Reaction to Ustekinumab
por: Walker, A., et al.
Publicado: (2022)

Bullous Wells Syndrome Induced by Ustekinumab
por: Kim, Yeona, et al.
Publicado: (2023)

Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder
por: Sprenger, Fabienne S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a36c119622id43ldtdbaja72j1